Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-06-10 Declaration of Voting R…
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2025, by Sagimet Biosciences Inc. It reports two main items: (1) Item 5.02 regarding departure and appointment of directors or officers and amended employment agreements with executive officers, and (2) Item 5.07 reporting the submission of matters to a vote of security holders at the 2025 Annual Meeting, including election of directors and ratification of the independent auditor. The content focuses on management changes and voting results from the annual meeting. The presence of detailed voting results and director elections aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual report, audit report, or earnings release, but a current report on material events including voting results and management changes. Therefore, the best classification is DVA with high confidence.
2025-06-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text includes a press release about clinical trial results and a new clinical trial initiation, furnished as an exhibit. There are no financial statements or detailed financial data presented, only a regulatory disclosure of a material event. The document is not an Annual Report, Earnings Release, or Interim Report. It is not a report publication announcement since it contains substantive disclosure itself. The Form 8-K is a regulatory filing used to inform investors of significant events. Therefore, the appropriate classification is Regulatory Filings (RNS). The confidence in this classification is high given the clear identification as a Form 8-K and the nature of the content.
2025-06-04 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-21 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-13 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the announcement of quarterly financial results for the quarter ended March 31, 2025, via a press release (Exhibit 99.1), and an updated investor presentation (Exhibit 99.2). The document itself does not contain detailed financial statements or substantive financial data but rather references these materials. The length of the document is 4560 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of financial results via press releases and presentations included as exhibits in an 8-K are classified as Earnings Release (ER) and Investor Presentation (IP), respectively. Since the main content is the announcement of quarterly financial results and the press release is furnished as an exhibit, the primary classification is Earnings Release (ER). The investor presentation is supplementary and also referenced. Therefore, the best fit is Earnings Release (ER) with high confidence.
2025-05-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.